US4810643A
(en)
|
1985-08-23 |
1989-03-07 |
Kirin- Amgen Inc. |
Production of pluripotent granulocyte colony-stimulating factor
|
US4933447A
(en)
|
1987-09-24 |
1990-06-12 |
Ss Pharmaceutical Co., Ltd. |
Quinoline derivatives
|
US6001826A
(en)
|
1989-12-21 |
1999-12-14 |
Anormed, Inc. |
Chemical compounds
|
US5021409A
(en)
|
1989-12-21 |
1991-06-04 |
Johnson Matthey Plc |
Antiviral cyclic polyamines
|
GB9126677D0
(en)
|
1991-12-16 |
1992-02-12 |
Johnson Matthey Plc |
Improvements in chemical compounds
|
GB9200245D0
(en)
|
1992-01-07 |
1992-02-26 |
British Bio Technology |
Compounds
|
US5235056A
(en)
|
1992-04-22 |
1993-08-10 |
Ciba-Geigy Corporation |
Substituted 1-hydroxy-2,6-diaryl-4-piperidone ketals and polymer compositions stabilized therewith
|
GB9400411D0
(en)
|
1994-01-11 |
1994-03-09 |
Johnson Matthey Plc |
Improvements in chemical compounds
|
GB9511357D0
(en)
|
1995-06-06 |
1995-08-02 |
Johnson Matthey Plc |
Improved antiviral compounds
|
US6506770B1
(en)
|
1996-06-06 |
2003-01-14 |
Anormed, Inc. |
Antiviral compounds
|
AU6887996A
(en)
|
1995-09-01 |
1997-04-01 |
Washington University School Of Medicine |
Method of reducing neurotoxic injury with zinc chelators
|
EE9800299A
(et)
|
1996-03-22 |
1999-06-15 |
The Du Pont Merck Pharmaceutical Company |
R-a-propüül-piperonüülamiini ja selle analoogide uudne asümmeetriline sünteesimine
|
CN1231215C
(zh)
|
1997-06-02 |
2005-12-14 |
詹森药业有限公司 |
(咪唑-5-基)甲基-2-喹啉酮衍生物用作平滑肌细胞增殖抑制剂
|
WO1999004794A1
(en)
|
1997-07-25 |
1999-02-04 |
Merck & Co., Inc. |
Cyclic amine modulators of chemokine receptor activity
|
AU9280698A
(en)
|
1997-09-30 |
1999-04-23 |
Daiichi Pharmaceutical Co., Ltd. |
Sulfonyl derivatives
|
GB9726229D0
(en)
|
1997-12-12 |
1998-02-11 |
Zeneca Ltd |
Resolution of chiral amines
|
HUP0100199A2
(hu)
|
1997-12-19 |
2001-04-28 |
Takeda Chemical Industries, Ltd. |
Anilid-származékot tartalmazó gyógyászati készítmény CCR5 antagonizálására
|
US6607799B1
(en)
|
1998-10-15 |
2003-08-19 |
3M Innovative Properties Company |
Surgical dressing with delivery system and method of manufacture
|
TWI230618B
(en)
*
|
1998-12-15 |
2005-04-11 |
Gilead Sciences Inc |
Pharmaceutical compositions of 9-[2-[[bis[(pivaloyloxy)methyl]phosphono]methoxy]ethyl]adenine and tablets or capsules containing the same
|
US6635278B1
(en)
|
1998-12-15 |
2003-10-21 |
Gilead Sciences, Inc. |
Pharmaceutical formulations
|
US6365583B1
(en)
|
1999-02-02 |
2002-04-02 |
Anormed, Inc. |
Methods to enhance white blood cell count
|
WO2000056729A1
(en)
|
1999-03-24 |
2000-09-28 |
Anormed Inc. |
Chemokine recpetor binding heterocyclic compounds
|
US6245799B1
(en)
|
1999-11-08 |
2001-06-12 |
American Home Products Corp |
[(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders
|
US6683192B2
(en)
|
2000-03-30 |
2004-01-27 |
Curis, Inc. |
Small organic molecule regulators of cell proliferation
|
PE20020354A1
(es)
|
2000-09-01 |
2002-06-12 |
Novartis Ag |
Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
|
NZ524420A
(en)
|
2000-09-15 |
2005-04-29 |
Anormed Inc |
Chemokine receptor binding heterocyclic compounds
|
IL154228A0
(en)
|
2000-09-15 |
2003-07-31 |
Anormed Inc |
Chemokin receptor binding heterocyclic compounds
|
IL154229A0
(en)
|
2000-09-15 |
2003-07-31 |
Anormed Inc |
Chemokine receptor binding heterocyclic compounds
|
JP4259877B2
(ja)
|
2000-12-11 |
2009-04-30 |
アムジエン・インコーポレーテツド |
Cxcr3アンタゴニスト
|
US6878714B2
(en)
|
2001-01-12 |
2005-04-12 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
GB0107228D0
(en)
|
2001-03-22 |
2001-05-16 |
Astrazeneca Ab |
Chemical compounds
|
US6794379B2
(en)
|
2001-06-06 |
2004-09-21 |
Tularik Inc. |
CXCR3 antagonists
|
US7169750B2
(en)
|
2001-07-31 |
2007-01-30 |
Anormed, Inc. |
Methods to mobilize progenitor/stem cells
|
ATE538785T1
(de)
|
2001-07-31 |
2012-01-15 |
Genzyme Global S A R L |
Verfahren zur mobilisierung von vorläufer/stammzellen
|
US8178123B2
(en)
|
2001-08-29 |
2012-05-15 |
Femina Pharma Incorporated |
Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
|
RU2308451C2
(ru)
|
2001-09-12 |
2007-10-20 |
Анормед, Инк. |
Способы получения рацемического аминозамещенного 5,6,7,8-тетрагидрохинолина или рацемического аминозамещенного 5,6,7,8-тетрагидроизохинолина, способы их разделения и рацемизации, способ получения кетозамещенного 5,6,7,8-тетрагидрохинолина или кетозамещенного 5,6,7,8-тетрагидроизохинолина, способ получения энантиомера конденсированного бициклического кольца, замещенного первичным амином, производные 5,6,7,8-тетрагидрохинолина
|
KR20040068339A
(ko)
|
2001-12-21 |
2004-07-30 |
아노르메드 인코포레이티드 |
효능이 강화된 케모카인 수용체 결합 헤테로사이클릭 화합물
|
US7354932B2
(en)
|
2001-12-21 |
2008-04-08 |
Anormed, Inc. |
Chemokine receptor binding heterocyclic compounds with enhanced efficacy
|
US7491544B2
(en)
|
2002-05-20 |
2009-02-17 |
New York University |
Chiral piperidine and quinucledine ligands
|
ATE419865T1
(de)
|
2002-08-14 |
2009-01-15 |
Silence Therapeutics Ag |
Verwendung von protein-kinase-n-beta
|
EP1571146A4
(en)
|
2002-12-10 |
2010-09-01 |
Ono Pharmaceutical Co |
NITROGENIC HETEROCYCLIC COMPOUNDS AND THEIR MEDICAL USE
|
CA2520259A1
(en)
|
2003-04-11 |
2004-10-28 |
Anormed Inc. |
Cxcr4 chemokine receptor binding compounds
|
JP4778420B2
(ja)
|
2003-04-22 |
2011-09-21 |
アノーメッド インコーポレイティド |
増強された有効性を有するケモカインレセプタ結合複素環式化合物
|
US7501518B2
(en)
|
2003-04-22 |
2009-03-10 |
Genzyme Corporation |
Methods of making 2,6-diaryl piperidine derivatives
|
US7498346B2
(en)
|
2003-12-11 |
2009-03-03 |
Genzyme Corporation |
Chemokine receptor binding compounds
|
US7332605B2
(en)
|
2004-03-15 |
2008-02-19 |
Anormed, Inc. |
Process for the synthesis of CXCR4 antagonist
|
WO2005100340A2
(en)
|
2004-04-13 |
2005-10-27 |
Icagen, Inc. |
Polycyclic pyridines as potassium ion channel modulators
|
DE102004021716A1
(de)
|
2004-04-30 |
2005-12-01 |
Grünenthal GmbH |
Substituierte Imidazo[1,2-a]pyridin-Verbindungen und Arzneimittel enthaltend substituierte Imidazo[1,2-a]pyridin-Verbindungen
|
WO2006020415A1
(en)
|
2004-08-02 |
2006-02-23 |
Smithkline Beecham Corporation |
Chemical compounds
|
CN101039672A
(zh)
|
2004-08-16 |
2007-09-19 |
史密丝克莱恩比彻姆公司 |
化合物
|
EP1799671A4
(en)
|
2004-09-02 |
2009-06-10 |
Smithkline Beecham Corp |
CHEMICAL COMPOUNDS
|
JP2008514622A
(ja)
|
2004-09-24 |
2008-05-08 |
スミスクライン ビーチャム コーポレーション |
化合物
|
TW200619206A
(en)
|
2004-09-29 |
2006-06-16 |
Anormed Inc |
Chemokine-binding heterocyclic compound salts, and methods of use thereof
|
JP2008531716A
(ja)
|
2005-03-04 |
2008-08-14 |
スミスクライン ビーチャム コーポレーション |
化合物
|
US20090203533A1
(en)
|
2005-07-08 |
2009-08-13 |
Siemens Medicals Solutions Diagnositcs Gmbh |
Methods and Kits for Predicting and Monitoring Direct Response to Cancer Therapy
|
WO2007008539A2
(en)
|
2005-07-11 |
2007-01-18 |
Smithkline Beecham Corporation |
Pyranopyridine compounds
|
BRPI0614256B1
(pt)
|
2005-08-02 |
2018-10-16 |
Ineos Europe Ltd |
processo para a produção de homopolímeros ou copolímeros de dienos conjugados
|
JP2009507795A
(ja)
|
2005-08-31 |
2009-02-26 |
スミスクライン ビーチャム コーポレーション |
化合物
|
PL1961744T3
(pl)
|
2005-11-18 |
2013-09-30 |
Ono Pharmaceutical Co |
Związek zawierający grupę zasadową oraz jego zastosowanie
|
CA2629037A1
(en)
|
2005-11-30 |
2007-06-07 |
Schering Corporation |
Compositions comprising a combination of ccr5 and cxcr4 antagonists
|
JP2009524689A
(ja)
|
2006-01-25 |
2009-07-02 |
スミスクライン ビーチャム コーポレーション |
化合物
|
AR059197A1
(es)
|
2006-01-25 |
2008-03-19 |
Smithkline Beecham Corp |
Derivados de indazolo piridina para el tratamiento de hiv
|
GB0605786D0
(en)
|
2006-03-22 |
2006-05-03 |
Glaxo Group Ltd |
Compounds
|
BRPI0712843A2
(pt)
|
2006-06-12 |
2012-07-31 |
Pfizer Prod Inc |
antagonista de ccr5 e seus usos
|
TWI482772B
(zh)
|
2006-08-21 |
2015-05-01 |
Astrazeneca Ab |
適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
|
CN101855222A
(zh)
|
2007-05-10 |
2010-10-06 |
通用电气健康护理有限公司 |
对大麻素cb2受体具有活性的咪唑并(1,2-a)吡啶和相关化合物
|
WO2009026251A1
(en)
|
2007-08-17 |
2009-02-26 |
The General Hospital Corporation |
Detecting ions and measuring ion concentrations
|
JP5690715B2
(ja)
|
2008-03-28 |
2015-03-25 |
アルテイリス・セラピユーテイクス |
ケモカイン受容体調節因子
|
WO2009151910A2
(en)
|
2008-05-25 |
2009-12-17 |
Wyeth |
Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
|
JP2010016628A
(ja)
|
2008-07-03 |
2010-01-21 |
Canon Inc |
画像処理装置及び画像処理方法
|
WO2010077613A1
(en)
|
2008-12-09 |
2010-07-08 |
Gilead Sciences, Inc. |
Modulators of toll-like receptors
|
WO2011036270A1
(en)
|
2009-09-28 |
2011-03-31 |
Kerry Group Services International Limited |
Pharmaceutical composition
|
US20110290821A1
(en)
|
2010-05-28 |
2011-12-01 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Anti-viral compositions and methods for administration
|
CA2706292A1
(en)
|
2010-05-28 |
2011-11-28 |
Pharmascience Inc. |
A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide
|
US9155723B2
(en)
|
2010-06-28 |
2015-10-13 |
The General Hospital Corporation |
Anti-CXCR4 as a sensitizer to cancer therapeutics
|
GB201017345D0
(en)
|
2010-10-14 |
2010-11-24 |
Proximagen Ltd |
Receptor antagonists
|
WO2012058241A2
(en)
|
2010-10-26 |
2012-05-03 |
University Of South Alabama |
Methods and compositions for ameliorating pancreatic cancer
|
CA2819468C
(en)
|
2010-12-03 |
2019-01-29 |
Emory University |
Chemokine cxcr4 receptor modulators and uses related thereto
|
EP2648754A4
(en)
|
2010-12-07 |
2016-02-24 |
Philadelphia Health & Educatio |
METHODS OF INHIBITING THE METASTASIS OF CANCER
|
PT3214091T
(pt)
|
2010-12-09 |
2019-01-11 |
Univ Pennsylvania |
Utilização de células t modificadas por recetor de antigénio quimérico para tratar o cancro
|
EP2663304B1
(en)
|
2011-01-11 |
2019-11-20 |
Dimerix Bioscience Pty Ltd |
Combination therapy
|
JP2014513727A
(ja)
*
|
2011-05-16 |
2014-06-05 |
ジェンザイム・コーポレーション |
Cxcr4拮抗薬の使用
|
AR087364A1
(es)
|
2011-07-29 |
2014-03-19 |
Pf Medicament |
Anticuerpo anti-cxcr4 y su uso para la deteccion y dianostico de canceres
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
CA2860995A1
(en)
|
2012-01-12 |
2013-07-18 |
Gilead Sciences, Inc. |
Pharmaceutical compositions and methods for their preparation
|
WO2014082083A1
(en)
|
2012-11-26 |
2014-05-30 |
Caris Science, Inc. |
Biomarker compositions and methods
|
US10064826B2
(en)
|
2013-03-15 |
2018-09-04 |
Navinta, Llc |
Direct compression and dry granulation processes for preparing carglumic acid tablets having less impurities than those produced by wet granulation process
|
AU2014274864B2
(en)
|
2013-06-05 |
2018-10-18 |
Salk Institute For Biological Studies |
Vitamin D receptor agonists to treat diseases involving CXCL12 activity
|
EP3030322A2
(en)
|
2013-08-05 |
2016-06-15 |
Cambridge Enterprise Limited |
Inhibition of cxcr4 signaling in cancer immunotherapy
|
SI3650014T1
(sl)
*
|
2013-08-27 |
2022-01-31 |
Gilead Pharmasset Llc |
Formulacija kombinacije dveh protivirusnih spojin
|
US10526660B2
(en)
|
2013-09-12 |
2020-01-07 |
Dana-Farber Cancer Institute, Inc. |
Methods for evaluating and treating Waldenstrom's macroglobulinemia
|
MX2016005925A
(es)
|
2013-11-05 |
2016-11-28 |
Cognate Bioservices Inc |
Combinaciones de inhibidores de punto de regulacion y terapeuticos para tratar el cancer.
|
US10280183B2
(en)
|
2014-03-18 |
2019-05-07 |
The Research Foundation For The State University Of New York |
Therapeutic agent for treating tumors
|
ES2913486T3
(es)
|
2014-03-19 |
2022-06-02 |
Infinity Pharmaceuticals Inc |
Compuestos heterocíclicos para la utilización en el tratamiento de trastornos mediados por PI3K-gamma
|
EP3157921A1
(en)
|
2014-06-23 |
2017-04-26 |
Dr. Reddy's Laboratories Ltd. |
Substituted imidazo[1,2-a]pyridine compounds useful for the treatment of pain
|
PL3169341T3
(pl)
|
2014-07-16 |
2019-12-31 |
Transgene Sa |
Wirus onkolityczny do ekspresji modulatorów punktu kontroli immunologicznej
|
US20180133327A1
(en)
|
2015-03-16 |
2018-05-17 |
Amal Therapeutics Sa |
Cell Penetrating Peptides and Complexes Comprising the Same
|
EP3307778A1
(en)
|
2015-06-12 |
2018-04-18 |
Bristol-Myers Squibb Company |
Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways
|
MX2018003058A
(es)
|
2015-09-14 |
2018-08-01 |
Infinity Pharmaceuticals Inc |
Formas solidas de derivados de isoquinolinona, proceso de fabricacion, composiciones que las contienen y metodos de uso de las mismas.
|
US10379661B2
(en)
|
2015-09-25 |
2019-08-13 |
Samsung Electronics Co., Ltd. |
Coordinate measuring apparatus and coordinate measuring system having the same
|
US11357742B2
(en)
|
2015-12-14 |
2022-06-14 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
EP3389634B1
(en)
|
2015-12-14 |
2021-10-06 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
JP7055380B2
(ja)
|
2015-12-22 |
2022-04-18 |
エックス4 ファーマシューティカルズ, インコーポレイテッド |
免疫不全疾患を処置するための方法
|
EP3405203A4
(en)
|
2016-01-22 |
2019-07-24 |
X4 Pharmaceuticals, Inc. |
METHODS OF TREATING CANCER
|
CA3019394A1
(en)
|
2016-04-08 |
2017-10-12 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
EP3443013A4
(en)
|
2016-04-14 |
2019-11-20 |
Creatv Microtech, Inc. |
METHOD FOR USE OF PD-L1 EXPRESSION IN TREATMENT DECISIONS FOR CANCER THERAPY
|
JP7084624B2
(ja)
|
2016-06-21 |
2022-06-15 |
エックス4 ファーマシューティカルズ, インコーポレイテッド |
Cxcr4阻害剤およびその使用
|
EP3472129A4
(en)
|
2016-06-21 |
2019-12-04 |
X4 Pharmaceuticals, Inc. |
CXCR4 INHIBITORS AND USES THEREOF
|
EP3808748A1
(en)
|
2016-06-21 |
2021-04-21 |
X4 Pharmaceuticals, Inc. |
Substituted piperidines as cxcr4-inhibitors
|
US20200138804A1
(en)
|
2017-06-21 |
2020-05-07 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
CN111465613A
(zh)
|
2017-11-07 |
2020-07-28 |
X4 制药有限公司 |
癌症生物标志物及其使用方法
|
WO2019126106A1
(en)
|
2017-12-19 |
2019-06-27 |
X4 Pharmaceuticals, Inc. |
Acyclic cxcr4 inhibitors and uses thereof
|
JP2021521439A
(ja)
|
2018-04-13 |
2021-08-26 |
エックス4 ファーマシューティカルズ, インコーポレイテッド |
がん血清バイオマーカーおよびその使用方法
|
US10548889B1
(en)
|
2018-08-31 |
2020-02-04 |
X4 Pharmaceuticals, Inc. |
Compositions of CXCR4 inhibitors and methods of preparation and use
|